Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Sep 22;218(Suppl 2):S88–S98. doi: 10.1093/infdis/jiy420

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2018. Published by Oxford University Press for the Infectious Diseases Society of America.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 3. — Zostavax vaccination leads to an increase in T-cell accumulation at the site of varicella zoster virus (VZV) antigen challenge. Punch biopsy specimens (diameter, 5 mm) were obtained on days 3 and 7 after VZV antigen challenge, before and after vaccination. A and B, Cumulative data showing number of CD4⁺ (A) and CD8⁺ (B) T cells per perivascular (PV) infiltrate before (black) and after (gray) vaccination on days 3 and 7 after VZV antigen challenge. C, Correlation between change in CD4⁺ (left) and CD8⁺ (right) T-cell number and change in clinical score after vaccine administration. D, Correlation between change in activated endothelium (calculated as the percentage of CD31⁺ loops expressing E-selectin) and change in clinical score after vaccine administration. For panels A and B, data were assessed by the Mann-Whitney test. For panels C and D, data were assessed by the Pearson correlation test.